Blockade of morphine-induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments

British Journal of Pharmacology

Volumn 151, Issue 1, 2007, Pages 75-83

  Cordonnier, L ^a,b,c   Sanchez, M ^d   Roques, B P ^c,e   Noble, F ^a,b,c  

^a CNRS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Clinique Montevideo   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

Amisulpride; Behavioral sensitization; Enkephalin; Locomotor activity; Opiates; RB101

Indexed keywords

AMISULPRIDE; BUPRENORPHINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; METHADONE; MORPHINE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; OPIATE; DISULFIDE; DRUG DERIVATIVE; PHENYLALANINE; SULPIRIDE; SULTOPRIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DEPENDENCE; LOCOMOTION; MALE; MONOTHERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; MOTOR ACTIVITY; OPIATE ADDICTION;

ANIMALS; BEHAVIOR, ANIMAL; BUPRENORPHINE; DISULFIDES; MALE; METHADONE; MICE; MORPHINE; MOTOR ACTIVITY; OPIOID-RELATED DISORDERS; PHENYLALANINE; SULPIRIDE;

EID: 34247565510     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707195     Document Type: Article

References (50)

1. Baik JH, Picetti R, Saiardi A, Thiriet G, Dierich A, Depaulis A et al. (1995). Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377: 424-428.
2. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S (2000). Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21: 1141-1146.
3. Bot G, Blake AD, Li S, Reisine T (1998). Mutagenesis of a single amino acid in the rat mu-opioid receptor discriminates ligand binding. J Neurochem 70: 358-365.
4. Browman KE, Badiani A, Robinson TE (1998). The influence of environment on the induction of sensitization to the psychomotor activating effects of intravenous cocaine in rats is dose-dependent. Psychopharmacology (Berlin) 137: 90-98.
5. Caboche J, Vernier P, Rogard M, Julien JF, Mallet J, Besson MJ (1992). Role of dopaminergic D2 receptors in the regulation of glutamic acid decarboxylase messenger RNA in the striatum of the rat. Eur J Neurosci 4: 438-447.
6. Cordonnier L, Sanchez M, Roques BP, Noble F (2005). Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neuroscience 135: 1-10.
7. Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R et al. (1992). 'Mixed inhibitor-prodrug' as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J Med Chem 35: 2473-2481.
8. Garrido MJ, Troconiz IF (1999). Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J Pharmacol Toxicol Methods 42: 61-66.
9. Gonzalez G, Oliveto A, Kosten TR (2004). Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 5: 713-725.
10. Gorman AL, Elliott KJ, Inturrisi CE (1997). The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 223: 5-8.
11. Hong JS, Yang HY, Fratta W, Costa E (1978). Rat striatal methionine-enkephalin content after chronic treatment with cataleptogenic and noncataleptogenic antischizophrenic drugs. J Pharmacol Exp Ther 205: 141-147.
12. Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001). Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297: 688-695.
13. Jaber M, Tison F, Fournier MC, Bloch B (1994). Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Brain Res Mol Brain Res 23: 14-20.
14. Johnson RE, Strain EC, Amass L (2003). Buprenorphine: how to use it right. Drug Alcohol Depend 70: S59-S77.
15. Kalivas PW, Bronson M (1985). Mesolimbic dopamine lesions produce an augmented behavioral response to enkephalin. Neuropharmacology 24: 931-936.
16. Kalivas PW, Duffy P (1987). Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons. J Pharmacol Exp Ther 241: 204-212.
17. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158: 360-369.
18. Kreek MJ (1997). Opiate and cocaine addictions: challenge for pharmacotherapies. Pharmacol Biochem Behav 57: 551-569.
19. Kreek MJ, Vocci FJ (2002). History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 23: 93-105.
20. Layson-Wolf C, Goode JV, Small RE (2002). Clinical use of methadone. J Pain Palliat Care Pharmacother 16: 29-59.
21. Lee KO, Akil H, Woods JH, Traynor JR (1999). Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol 378: 323-330.
22. Maldonado R, Dauge V, Feger J, Roques BP (1990). Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats. Neuropharmacology 29: 215-223.
23. Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP, Borrelli E (1997). Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 388: 586-589.
24. Mas Nieto M, Wilson J, Cupo A, Roques BP, Noble F (2002). Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: a microdialysis study. J Neurosci 22: 1034-1041.
25. Mello NK, Negus SS (1996). Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14: 375-424.
26. Migaud M, Durieux C, Viereck J, Soroca-Lucas E, Fournié-Zaluski MC, Roques BP (1996). The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 17: 601-607.
27. Montiel JL, Cornille F, Roques BP, Noble F (1997). Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. J Neurochem 68: 354-361.
28. Noble F, Roques BP (1995). Assessment of endogenous enkephalins efficacy in the hot plate test in mice: comparative study with morphine. Neurosci Lett 185: 75-78.
29. Noble F, Roques BP (2002). Inhibitors of enkephalin catabolism. In: Maldonado R (ed). New Therapeutic Tool in Opiate Dependence. Molecular Biology of Addiction. Humana Press Inc.: Totowa, NJ, pp 61-75.
30. Noble F, Soleilhac JM, Soroca-Lucas E, Turcaud S, Fournié-Zaluski MC, Roques BP (1992). Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 261: 181-190.
31. Normand E, Popovici T, Fellmann D, Bloch B (1987). Anatomical study of enkephalin gene expression in the rat forebrain following haloperidol treatment. Neurosci Lett 83: 232-236.
32. Normand E, Popovici T, Onteniente B, Fellmann D, Piatier-Tonneau D, Auffray C et al. (1988). Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons. Brain Res 439: 39-46.
33. Robinson TE, Browman KE, Crombag HS, Badiani A (1998). Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 22: 347-354.
34. Romero DV, Partilla JS, Zheng QX, Heyliger SO, Ni Q, Rice KC et al. (1999). Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay. Synapse 34: 83-94.
35. Roques BP, Noble F (1995). Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. NIDA Res Monogr 147: 104-145.
36. Roques BP, Noble F (2004). Inhibitors of enkephalin-degrading enzymes and delta-opioid responses. In: Chang KJ, Porreca F, Woods JH (eds). The Delta Receptor. Marcel Dekker Inc.: New York, Basel, pp 277-296.
37. Roques BP, Noble F, Dauge V, Fournié-Zaluski MC, Beaumont A (1993). Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45: 87-146.
38. Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR (1997). mu-Opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 51: 87-96.
39. Spanagel R, Almeida OF, Shippenberg TS (1993). Long lasting changes in morphine-induced mesolimbic dopamine release after chronic morphine exposure. Synapse 14: 243-245.
40. Sung S, Conry JM (2006). Role of buprenorphine in the management of heroin addiction (March). Ann Pharmacother 40: 501-505.
41. Tang F, Costa E, Schwartz JP (1983). Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2-3 weeks. Proc Natl Acad Sci USA 80: 3841-3844.
42. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L et al. (1998). Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178: 440-466.
43. Turner AJ, Hooper NM, Kenny AJ (1987). Metabolism of neuropeptides. In: Kenny AJ and Turner AJ (eds). Mammalian Ectoenzymes. Elsevier: Amsterdam, pp 211-248.
44. Traynor JR, Nahorski SR (1995). Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47: 848-854.
45. Tzschentke TM (2002). Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berlin) 161: 1-16.
46. Uchtenhagen A (2003). Substitution management in opioid dependence. J Neural Transm (Suppl 66): 33-60.
47. Vanderschuren LJ, Kalivas PW (2000). Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berlin) 151: 99-120.
48. van Ree JM, Gerrits MA, Vanderschuren LJ (1999). Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol Rev 51: 341-396.
49. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M (1999). Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23: 737-746.
50. Zhao WL, Gong ZH, Liang JH (2004). A new buprenorphine analogy, thenorphine, inhibits morphine-induced behavioral sensitization in mice. Acta Pharmacol Sin 25: 1413-1418.